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Introduction {#sec001}
============

During endochondral ossification, bones are formed by a multistep process, which includes the formation of a cartilage template of the later skeletal element and its subsequent replacement by bone. The cartilage anlagen originate in mesenchymal cells, which condense and differentiate into chondrocytes. These chondrocytes proliferate and express the extracellular matrix protein Collagen type 2 (Col2) \[[@pone.0218230.ref001]\]. Two subtypes of proliferating chondrocytes can be distinguished: round, slow proliferating cells at the end of the cartilage elements (round/resting chondrocytes) and flat, highly proliferating cells organized in columns towards the hypertrophic region (columnar chondrocytes). When the cartilage anlagen reach a critical size, proliferating chondrocytes in their center exit the cell cycle and differentiate into Indian hedgehog (Ihh) producing, prehypertrophic \[[@pone.0218230.ref002], [@pone.0218230.ref003]\] and, subsequently, Collagen type 10 (Col10) expressing, hypertrophic chondrocytes \[[@pone.0218230.ref004]\]. Eventually, blood vessels invade the zone of hypertrophic chondrocytes and the hypertrophic cells are replaced by bone and bone marrow. Postnatally, secondary ossification centers (SOC) are formed at the ends of the endochondral long bones. Between the two regions of ossification, parts of the embryonic cartilage, the so-called growth plates, remain to organize longitudinal growth after birth \[[@pone.0218230.ref005]\]. As longitudinal bone growth depends on the balance between chondrocyte proliferation and hypertrophic differentiation, both processes are tightly regulated. Although many regulators have been identified, clarifying the detailed molecular mechanisms is still in progress.

Atonal homolog 8 (Atoh8, also known as Math6 in mouse) is a transcription factor of the basic helix-loop-helix (bHLH) protein family \[[@pone.0218230.ref006]\]. The helix-loop-helix region of these proteins mediates the interaction with other bHLH proteins, while their basic region binds to a specific DNA sequence, the E-box element \[[@pone.0218230.ref007]\].

In contrast to other atonal-related proteins, which show a tissue restricted pattern of expression, Atoh8 is broadly expressed in many organs including the brain, kidney and skeletal muscles and regulates proliferation and differentiation of distinct cell types. For instance, overexpression of Atoh8 in retinal explant cultures promotes the differentiation of neuronal progenitors towards the neuronal versus the glial cell lineage \[[@pone.0218230.ref006]\]. Consistent with this, Atoh8 is necessary for the differentiation of the hypaxial muscles of the trunk in chicken embryos, which underpins its importance for the proliferation-to-differentiation transition in embryonic development \[[@pone.0218230.ref008]\]. In mice, loss of Atoh8 expression leads to podocyte dedifferentiation during kidney development \[[@pone.0218230.ref009]\]. In addition, Atoh8 has been described as an activator of proliferation during muscle regeneration \[[@pone.0218230.ref010]\] and in colorectal cancer \[[@pone.0218230.ref011]\].

In the developing skeleton, Atoh8 has been shown to be expressed in avian growth plates \[[@pone.0218230.ref012]\] and in mouse limb buds \[[@pone.0218230.ref013], [@pone.0218230.ref014]\], but its molecular role has not been investigated.

In this study, we show that Atoh8 deficiency results in reduced zones of proliferating and hypertrophic chondrocytes and, consequently, in a decreased length of endochondral bones. In addition, we observed a reduced proliferation rate due to Atoh8 depletion suggesting Atoh8 positively regulates chondrocyte proliferation. Moreover, the altered domain of proliferating chondrocytes indicates an additional function as a regulator of hypertrophy. In limb explant cultures, we found Atoh8 to regulate the onset of chondrocyte differentiation upstream of Ihh, while it acts independent or downstream of Ihh in the regulation of proliferation.

Materials and methods {#sec002}
=====================

Transgenic mice and genotyping {#sec003}
------------------------------

All animal experiments were performed according to the institutional guidelines of the University Duisburg-Essen, specifically approved by the animal welfare officer of the University Duisburg-Essen. Mouse husbandry was approved by the city of Essen (Az: 32-2-11-80-71/348) in accordance with § 11-1a of the "Tierschutzgesetz". Work with transgenic animals and BrdU injection was approved by the "Bezirksregierung Duesseldorf" (Az: 53.02.01-D-1.55/12, Anlagen-Nr. 1464 (transgenic) and 84--02.05.20.12.157, Anlage-Nr. B1294/12 (BrdU)) in accordance with § 8 Abs. 4 Satz 2 GenTG of the "Gentechnikgesetz". *Col2a1-Cre* \[[@pone.0218230.ref015]\] or *Prx1-Cre* \[[@pone.0218230.ref016]\] mice were interbred with *Atoh8*^*flox/flox*^ mice \[[@pone.0218230.ref017]\] and the resulting *Atoh8*^*flox/+*^*;Col2a1-Cre* or *Atoh8*^*flox/+*^*;Prx1-Cre*^*female*^ mice were backcrossed to *Atoh8*^*flox/flox*^ mice to generate *Atoh8*^*flox/flox*^*;Col2a1-Cre* or *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ mutants. As controls, corresponding littermates without the *Col2a1-Cre* or *Prx1-Cre* allele were used. In addition, heterozygous *Atoh8*^*flox/+*^*;Col2a1-Cre* or *Atoh8*^*flox/+*^*;Prx1-Cre*^*female*^ littermates were analyzed as Cre-positive controls. All strains were maintained on a C57BL/6J genetic background. Genotyping of tail DNA was performed using the following primers: *Atoh8*, forward (Atoh8-fwd): `5´-GGAAAGTTCCTACTCGTCAATTTCACACG-3´` and reverse (Atoh8-rev): `5´-CCAAGGGACCAGAAGACAAATACTCGC-3´`; *Col2a1-Cre* or *Prx1-Cre* transgene, forward: `5´-GAGTGATGAGGTTCGCAAGA-3´` and reverse`: 5´-CTACACCAGAGACGG-3´`; to control Cre mediated excision, forward (Ex-fwd): `5´-AGCCTCTTCTTTCTAGTAGGATTTCCAGTGG-3´` and reverse (Ex-rev): `5´-CTCTGTCCTTCTCAGTCAACAAGATGATGTC-3´`. Wild-type mice (NMRI) were obtained from Charles River Laboratories.

Histology {#sec004}
---------

For histological analysis, forelimbs of E12.5-E18.5 embryos and P7-P14 mice were fixed overnight in 4% paraformaldehyde at 4°C. Forelimbs of P7-P14 mice were decalcified in 25% EDTA for at least one week at 37°C. After dehydration and embedding in paraffin, serial sections of 4--5 μm (prenatal stages) or 7 μm (postnatal stages) were stained with Safranin-Weigert as described previously \[[@pone.0218230.ref018]\] or used for *in situ* hybridization or BrdU labeling.

All length measurements were carried out on sections covering the entire skeletal element.

*In situ* hybridization {#sec005}
-----------------------

For fluorescence *in situ* hybridization, RNA antisense probes were labeled with Digoxigenin-11-UTP (Roche). Hybridization was performed as described previously \[[@pone.0218230.ref019]\]. DNA was counterstained with 5 mg/ml DAPI (Roth).

For whole-mount *in situ* hybridization, RNA antisense and sense probes were labeled with Digoxigenin-11-UTP (Roche). Embryo preparation and hybridization was performed as described previously \[[@pone.0218230.ref020]\] using α-Digoxigenin-AP (Roche) and NBT-BCIP solution (Sigma) for detection \[[@pone.0218230.ref021]\].

The following probes were used for *in situ* hybridization: rat *Col2a1* \[[@pone.0218230.ref022]\], mouse *Ihh* \[[@pone.0218230.ref023]\], mouse *Col10a1* \[[@pone.0218230.ref024]\] and mouse *Atoh8* using a 770 bp fragment corresponding to nucleotides 445--1214 of mouse Atoh8 mRNA subcloned into pDrive.

For measurements, 2 -- 6 sections were analyzed per animal.

Skeletal preparation {#sec006}
--------------------

Six month old, male mice were skinned, eviscerated and fixed in 100% ethanol overnight at 4°C. Alcian blue and Alizarin red staining and subsequent clearing in 1% potassium hydroxide were carried out as described previously. Samples were stored in 100% glycerol \[[@pone.0218230.ref025]\].

BrdU labeling {#sec007}
-------------

To analyze chondrocyte proliferation pregnant (14.5 days post fertilization) and P7 mice received an intraperitoneal injection of 16 μl/kg and 20 μl/kg body weight BrdU (10 mM), respectively, 2 h before being sacrificed as described previously \[[@pone.0218230.ref026]\]. Limb explants were treated for 2 h with 0.1 mM BrdU. Sections of forelimbs or limb explants were stained with a rat α-BrdU (Abcam) antibody and detected with an Alexa 568 goat α-rat (Life Technologies) secondary antibody. DNA was counterstained with 5 mg/ml DAPI (Roth). BrdU labelled and total cell numbers were scored in defined regions of 3--9 sections per animal using the Metamorph imaging software (Visitron Systems) or a combination of Fiji and CellProfiler.

Limb explant cultures {#sec008}
---------------------

For limb explant cultures, forelimbs were dissected from E16.5 embryos and skin and muscle tissue were removed. Limb explants were cultured for 48 h (proliferation analysis) or 96 h (*in situ* hybridization) as described previously \[[@pone.0218230.ref027]\]. One forelimb of each embryo was treated with 4 μM Purmorphamine (Abcam) while the second forelimb served as a control and was treated with an equivalent amount of DMSO (AppliChem). After culture, limb explants were fixed and embedded.

Micromass cultures and Alcian blue staining {#sec009}
-------------------------------------------

Primary chondrocytes were isolated from limb buds of E12.5 embryos by digestion with 1 U/ml Neutral Protease NB (Serva) for 15 min and with 0.3 U/ml collagenase NB 4 (Serva)/0.05% trypsin-EDTA (Life Technologies) for 30 min at 37°C. Single cell suspensions were obtained by passing through a 40-μm cell strainer. 2·10^7^ cells were cultured in high-density as described previously \[[@pone.0218230.ref028]\]. For differentiation into hypertrophic chondrocytes, micromass cultures were cultured for 28 days. Afterwards, micromass cultures were fixed and stained with Alcian blue \[[@pone.0218230.ref028]\].

Cell culture {#sec010}
------------

ATDC5 cells \[[@pone.0218230.ref029]\] were cultured in DMEM (Thermo Fisher Scientific) with 5% fetal calf serum (PAN-Biotech) and 1% Penicillin/Streptomycin (Thermo Fisher Scientific). The human Atoh8 expression plasmid \[[@pone.0218230.ref030]\] was transfected by electropulsing using the Cell Line Nucleofector System (Lonza) following standard procedures provided by the manufacturers.

Quantitative reverse transcription PCR (qRT-PCR) {#sec011}
------------------------------------------------

RNA was extracted from micromass cultures, embryos or forelimb skeletal elements using the NucleoSpin RNA kit (Macherey-Nagel). cDNA was synthesized with the Maxima First Strand cDNA Synthesis Kit for RT-qPCR (Thermo Scientific). qRT-PCR was performed with a 1:2 dilution of cDNA by using the StepOnePlus Real-Time PCR-System (Thermo Fisher Scientific) or the CFX384 Touch^TM^ Real-Time PCR detection system (Bio-Rad) with the my-Budget 5x EvaGreen (R) QPCR-Mix II (BioBudget). All mRNA quantification data were normalized to Beta-2 microglobulin (B2M). Relative quantity of mRNA was calculated by the ΔCt method. The following primer pairs were used: for Atoh8, forward: `5´-CTTCGAGGCGCTGAGGAAG-3´` and reverse: `5´-GCAGGTCACTCCTTCCGTTT-3´`; for Col2, forward: `5´-CGAGTGGAAGAGCGGAGACT-3´` and reverse: `5´-AACTTTCATGGCGTCCAAGGT-3´`; for Ihh, forward: `5´-TCAGACCGTGACCGAAATAA-3´` and reverse: `5´-ACACGCTCCCCGTTCTCTA-3´`; for B2M, forward: `5´-TCGGCGCTTCAGTCGCGGTCG-3´` and reverse: `5´-TCCCATTCTCCGGTGGGTGGCGT-3´`. Additional primer pairs used for [S4 Fig](#pone.0218230.s004){ref-type="supplementary-material"} are listed in [S2 Table](#pone.0218230.s006){ref-type="supplementary-material"}.

Imaging {#sec012}
-------

Bright and dark field pictures were taken on a Zeiss Axioplan 2 microscope with a SPOT 14.2 camera and SPOT advanced software (Diagnostic Instruments), radioactive *in situ* hybridization signals were visualized using the illuminator Intralux 5000--1 (Volpi). Fluorescence pictures were taken on a Zeiss Axiovert 200 microscope with a Spot 23.0 camera (Diagnostic Instruments) and Metamorph imaging software (Visitron Imaging Systems) or a Zeiss Axio Observer 7 microscope with an AxioCam 506 mono CCD camera (Zeiss) and Zen 2.3 software (Zeiss).

Statistical analysis {#sec013}
--------------------

Probabilities *p*~*-*~ and *p*~*+*~ (effect direction probabilities) that Atoh8 deletion is associated with a negative or positive effect, respectively, on the measured quantities were estimated by Bayesian inference with Generalized Linear Models (GLMs). Specifically, if the measured quantities were continuous and positive (distances, or, in qPCR measurements, relative expressions), we modeled the measurements as generated by a linear model linked to the measurement scale by a logarithm, and with a normal noise distribution; if the measured quantities were counts (BrdU experiments), measurements were considered as generated by a linear model linked by a logit-function to a binomial probability parameter, and finally a binomial distribution producing the observed data. In all linear parts of the GLMs, effects coming from batches, litters, or animals were treated as separate intercepts in the linear model. Priors for all fitted parameters were chosen much broader than the distribution of the actual data so that the posteriors are mainly determined by the data. Models were fitted with the default sampler of the Stan software, version 2.17 \[[@pone.0218230.ref031]\], typically with three Markov chains, each of several thousand iterations. Convergence of Markov chains was monitored with the Gelman-Rubin diagnostic parameter Ȓ, which was lower than 1.02 in all cases, and the effective sample size, typically in the hundreds or thousands. Posterior predictive checks were carried out to test consistency of all fitted models with the data of the respective experiments. Finally, *p*~*-*~ and *p*~*+*~ values were computed by sampling from the fitted posterior the strength of the effect of interest (e.g. the effect of the genotype) on the measured quantity. All *p*~-~ and *p*~+~ values are listed in [S1 Table](#pone.0218230.s005){ref-type="supplementary-material"}. The interpretation of effect direction probabilities *p*~*-*~ and *p*~*+*~ is simple: e.g. if we are interested in the effect of Atoh8 on Col2 expression ([Fig 1E](#pone.0218230.g001){ref-type="fig"}), the value *p*~*-*~ = 0.984 at day 7 means that a negative effect of the Atoh8-knockout on Col2 expression has a probability of 0.984; accordingly, the probability of a positive effect is *p*~*+*~ *=* 1-*p*~*-*~ = 0.016. All effect direction probabilities are given to 3 digits. Effect direction probabilities *p*~*-*~ ≥ 0.950 and *p*~+~ ≤ 0.050 or vice versa are regarded to be significant. To analyze if the effects of the Purmorphamine treatment varied between the genotypes, two GLMs were developed. In one model genotype and treatment effects were added with an interaction and in the other model without an interaction. We then compared the two models for their ability to generalize to unseen data by an approximate leave-one-out cross-validation \[[@pone.0218230.ref032]\]. Data in bar plots are presented as mean ± standard deviation. Standard deviations are shown as error bars in all bar plots. n always corresponds to biological replicates.

![Atoh8 expression profile.\
(A) Whole-mount *in situ* hybridization of E12.5 wild-type embryos with an *Atoh8* sense and antisense probe reveals Atoh8 expression in mouse limb buds. (B) A magnified view of the limb buds framed in A shows Atoh8 expression in the cartilage anlagen (black arrows) overlapping with the expression of Col2 (C). (D) Parallel sections of an E14.5 wild-type forelimb hybridized with *Atoh8*, *Col2* and *Col10* antisense probes. Atoh8 is expressed in proliferating and hypertrophic chondrocytes with an increased expression in prehypertrophic chondrocytes (black arrows). (E) Schematic representation of a developing long bone at E14.5 to visualize Col2 (red left-right arrows) and Col10 (green left-right arrow) expression domains and the zones of different chondrocyte populations. PC = proliferating chondrocytes, PH = prehypertrophic chondrocytes, HC = hypertrophic chondrocytes. (F, G) Relative Atoh8 (F) and Col2 (G) mRNA expression of chondrocytes cultured in micromass culture for up to 28 days in differentiation medium. Primary chondrocytes were isolated from E12.5 *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ embryos and control littermates. n = 4 control and 3 *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ mice from 1 litter; Bayesian analysis. Scale bar (white lines) in D: 500 μm.](pone.0218230.g001){#pone.0218230.g001}

Results {#sec014}
=======

Atoh8 is expressed in proliferating and hypertrophic chondrocytes {#sec015}
-----------------------------------------------------------------

To receive first insight into the role of Atoh8 in skeletal development, we investigated its detailed expression pattern in mouse skeletal tissues. Whole-mount *in situ* hybridization of E12.5 embryos confirmed the expression in early limb buds, particularly in the developing cartilage anlagen ([Fig 1A--1C](#pone.0218230.g001){ref-type="fig"}) \[[@pone.0218230.ref013], [@pone.0218230.ref014]\]. In order to determine the specific expression of Atoh8 in chondrocytes, we compared its expression to that of Col2 and Col10, markers of proliferating and hypertrophic chondrocytes, respectively. *In situ* hybridization on parallel sections of E14.5 wild-type limbs revealed that Atoh8 is expressed in both, proliferating and hypertrophic chondrocytes ([Fig 1D and 1E](#pone.0218230.g001){ref-type="fig"}) with an increased level of expression in prehypertrophic chondrocytes ([Fig 1D](#pone.0218230.g001){ref-type="fig"}, arrows). Furthermore, we analyzed Atoh8 expression during the differentiation of primary chondrocytes in micromass cultures by qRT-PCR. High Atoh8 expression was detected at day 7 of culture, while it continued to be expressed at lower levels until at least day 28 when hypertrophic differentiation has taken place as demonstrated by the decrease in Col2 expression ([Fig 1F and 1G](#pone.0218230.g001){ref-type="fig"}).

In contrast to Atoh8, no other *Atoh* gene is expressed in chondrocytes, as no noteworthy mRNA expression is detectable via qRT-PCR in control or Atoh8-deficient developing skeletal elements ([S4 Fig](#pone.0218230.s004){ref-type="supplementary-material"}).

Chondrocyte-specific deletion of Atoh8 results in reduced bone length due to disturbed chondrocyte proliferation and differentiation at postnatal stages {#sec016}
--------------------------------------------------------------------------------------------------------------------------------------------------------

In order to determine the role of Atoh8 during endochondral ossification we analyzed mice carrying a chondrocyte-specific deletion of Atoh8. For this purpose, we used a conditional allele of Atoh8, in which Exon1 is flanked by *loxP* sites ([S1 Fig](#pone.0218230.s001){ref-type="supplementary-material"}) \[[@pone.0218230.ref017]\], and deleted Exon1 of *Atoh8* specifically in chondrocytes using a Col2a1-Cre driver \[[@pone.0218230.ref015]\]. Both, hetero- and homozygous mutants were born in Mendelian ratios and were viable and fertile. Besides a slightly reduced body size, *Atoh8*^*flox/flox*^*;Col2a1-Cre* mutants did not show any obvious phenotypes.

To investigate the skeletal phenotype of the mutants in detail, we analyzed Safranin-Weigert stained forelimb sections of embryonic and juvenile mice and Alcian blue/Alizarin red stained adult skeletons. We could not detect distinct differences between mutant and control mice at prenatal stages ([S3 Fig](#pone.0218230.s003){ref-type="supplementary-material"}). However, from early postnatal stages (P7 and P14) until adulthood (6 month) the skeletal size was reduced in *Atoh8*^*flox/flox*^*;Col2a1-Cre* mice ([Fig 2](#pone.0218230.g002){ref-type="fig"}). Measuring the length of the radius as a representative bone revealed a slight, but significant reduction in *Atoh8*^*flox/flox*^*;Col2a1-Cre* mice at P7 (-13.5%, *p*~*+*~ \< 0.001), P14 (-14.7%, *p*~*+*~ \< 0.001) and 6 month (-7.3%, *p*~*+*~ = 0.003) ([Fig 2B and 2C](#pone.0218230.g002){ref-type="fig"}). This reduction in bone length is more pronounced in mice with homozygous than with heterozygous Atoh8 deletion ([S2A Fig](#pone.0218230.s002){ref-type="supplementary-material"}).

![Postnatal *Atoh8*^*flox/flox*^*;Col2a1-Cre* mice show a reduced skeletal size.\
(A) Skeletal preparations of six month old mice show that *Atoh8*^*flox/flox*^*;Col2a1-Cre* mutant mice are smaller than their control littermates. (B, C) The radius of adult (6 month) and juvenile (P7, P14) *Atoh8*^*flox/flox*^*;Col2a1-Cre* mutants is significantly shorter than that of control littermates. (B) Measurements for C are visualized with white (control) and black (mutant) left-right arrows. n = 10 control and 8 *Atoh8*^*flox/flox*^*;Col2a1-Cre* mice from 5 litters (P7), n = 8 control and *Atoh8*^*flox/flox*^*;Col2a1-Cre* mice from 5 litters (P14), n = 3 control and *Atoh8*^*flox/flox*^*;Col2a1-Cre* mice from 2 litters (6 month); Bayesian analysis. Scale bar (black lines) in B: 1 mm.](pone.0218230.g002){#pone.0218230.g002}

To determine the molecular basis for the reduced bone length in *Atoh8*^*flox/flox*^*;Col2a1-Cre* mice, we analyzed the size of the cartilage region including proliferating and hypertrophic chondrocytes on sections of P7 mice after Safranin-Weigert staining. Compared to control littermates, we found it to be shortened in *Atoh8*^*flox/flox*^*;Col2a1-Cre* mice ([Fig 3A](#pone.0218230.g003){ref-type="fig"} top) indicating that the reduced bone length is due to impaired chondrocyte proliferation and/or differentiation. To investigate which step of the differentiation program is affected, we analyzed the expression of Col2 and Col10, markers for proliferating and hypertrophic chondrocytes, respectively, on parallel sections of P7 forelimbs by *in situ* hybridization. In order to determine if the onset of hypertrophy is disturbed, we measured the distance of the Col10 expression zone to the joint as well as the length of the Col2 expression zone, which demarcate the region of proliferating chondrocytes. Both zones were decreased in P7 *Atoh8*^*flox/flox*^*;Col2a1-Cre* mutants (*p*~*+*~ = 0.009 and *p*~*+*~ = 0.025) ([Fig 3B--3D](#pone.0218230.g003){ref-type="fig"}) pointing to a premature onset of hypertrophic differentiation. Furthermore, the zone of Col10 expressing hypertrophic chondrocytes was shortened in P7 *Atoh8*^*flox/flox*^*;Col2a1-Cre* mutants (*p*~*+*~ = 0.022) ([Fig 3B--3D](#pone.0218230.g003){ref-type="fig"}) indicating that in addition the process of hypertrophic differentiation is accelerated. To investigate, whether a reduced proliferation rate also contributes to the reduced skeletal size, we analyzed cells in S-phase after bromodesoxyuridine (BrdU) incorporation. We found that the proliferation rate of round and columnar proliferating chondrocytes is reduced by 1.4 (*p*~*+*~ = 0.003) and 5.4% (*p*~*+*~ = 0.004), respectively, in *Atoh8*^*flox/flox*^*;Col2a1-Cre* mutants ([Fig 3E and 3F](#pone.0218230.g003){ref-type="fig"}).

![*Atoh8*^*flox/flox*^*;Col2a1-Cre* mice show reduced chondrocyte proliferation and accelerated hypertrophic differentiation at postnatal stages.\
(A) Sections of P7 and P14 control and *Atoh8*^*flox/flox*^*;Col2a1-Cre* forelimbs stained with Safranin-Weigert. The zone of chondrocytes in the radius is shortened in P7 *Atoh8*^*flox/flox*^*;Col2a1-Cre* mutants as visualized by white (control) and black (mutant) left-right arrows. Furthermore, the formation of the SOC (black arrows) is delayed in *Atoh8*^*flox/flox*^*;Col2a1-Cre* limbs. (B-D) *In situ* hybridization of parallel control and *Atoh8*^*flox/flox*^*;Col2a1-Cre* forelimb sections with a *Col2* and *Col10* antisense probe revealed an accelerated onset and process of hypertrophic differentiation in P7 *Atoh8*^*flox/flox*^*;Col2a1-Cre* mice. Measurements for D are visualized with white (control) and red (mutant) left-right arrows (B) and with red (Col2) and green (Col10) left-right arrows in the schematic representation of the developing long bone (C). (C) PC = proliferating chondrocytes, PH = prehypertrophic chondrocytes, HC = hypertrophic chondrocytes, SOC = secondary ossification center. (E, F) BrdU labeling of P7 control and *Atoh8*^*flox/flox*^*;Col2a1-Cre* forelimb sections revealed a significantly reduced proliferation rate in round and columnar chondrocytes in *Atoh8*^*flox/flox*^*;Col2a1-Cre* mice. Regions of round and columnar chondrocytes analyzed in F are framed with white boxes. (D) n = 4 control and 3 *Atoh8*^*flox/flox*^*;Col2a1-Cre* mice from 2 litters; (F) n = 6 control and 4 *Atoh8*^*flox/flox*^*;Col2a1-Cre* mice from 3 litters; (D, F) Bayesian analysis. Scale bar in A (black lines) and B (white lines): 500 μm and in E (white lines): 200 μm.](pone.0218230.g003){#pone.0218230.g003}

Besides the reduced region of proliferating chondrocytes, Safranin-Weigert stained forelimb sections of *Atoh8*^*flox/flox*^*;Col2a1-Cre* mice showed a reduced zone of hypertrophic chondrocytes at the ends of the long bones, where the formation of the SOC is initiated, at P7 ([Fig 3A](#pone.0218230.g003){ref-type="fig"} top, arrows) and, consequently, a reduced SOC at P14 ([Fig 3A](#pone.0218230.g003){ref-type="fig"} bottom, arrows).

Taken together, our analyses identified Atoh8 as a regulator of chondrocyte proliferation and differentiation during postnatal bone growth.

Ubiquitous deletion of Atoh8 reduces chondrocyte proliferation and accelerates the onset of hypertrophic differentiation at prenatal stages {#sec017}
-------------------------------------------------------------------------------------------------------------------------------------------

To decipher if ubiquitous deletion of Atoh8 results in a stronger phenotype than the chondrocyte-specific deletion, we used a female-transmitted *Prx1-Cre* allele, which leads to the expression of Cre recombinase in the germline \[[@pone.0218230.ref016]\]. Both, heterozygous and homozygous mutants were viable. Genotyping ([S1 Fig](#pone.0218230.s001){ref-type="supplementary-material"}) of tissue from the tail, in which Prx1 is not expressed, confirmed the ubiquitous recombination of the allele. Furthermore, qRT-PCR of micromass cultures, which besides chondrocytes contain a mixed population of mesenchymal cells, did not detect Atoh8 mRNA expression in cultures of *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ mice ([Fig 1F](#pone.0218230.g001){ref-type="fig"}).

To detect differences in size of the embryonic skeleton, we measured the length of the radius on Safranin-Weigert stained sections of E16.5 ([Fig 4A](#pone.0218230.g004){ref-type="fig"}) and E14.5 ([Fig 5A](#pone.0218230.g005){ref-type="fig"}) embryos. We found that the radius of *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ mice was significantly shorter than that of control and *Atoh8*^*flox/+*^*;Prx1-Cre*^*female*^ mice at both embryonic stages with *p*~*+*~ = 0.005/0.027 for E16.5 ([Fig 4A and 4B](#pone.0218230.g004){ref-type="fig"} and [S2C Fig](#pone.0218230.s002){ref-type="supplementary-material"}) and *p*~*+*~ \< 0.001 for E14.5 ([Fig 5A and 5B](#pone.0218230.g005){ref-type="fig"} and [S2B Fig](#pone.0218230.s002){ref-type="supplementary-material"}).

![*Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ mice show a reduced skeletal size at prenatal stages.\
(A, B) Sections of E16.5 control and *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ forelimbs stained with Safranin-Weigert. The radius of E16.5 *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ mutants is significantly shorter than that of control littermates. Measurements for B are visualized with white (control) and black (mutant) left-right arrows. (C-E) Parallel sections of E16.5 control and *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ forelimbs hybridized with a *Col2*, *Ihh and Col10* antisense probe show an accelerated hypertrophic differentiation in mutant mice. Measurements for E are visualized with white (control) and red (mutant) left-right arrows (C) and with red (Col2), yellow (Ihh) and green (Col10) left-right arrows in the schematic representation of the developing long bone (D). (D) PC = proliferating chondrocytes, PH = prehypertrophic chondrocytes, HC = hypertrophic chondrocytes. (B) n = 5 control and *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ mice from 2 litters; (E) n = 3 control and *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ mice from 1 litter; (B, E) Bayesian analysis. Scale bar in A (black lines) and C (white lines): 500 μm.](pone.0218230.g004){#pone.0218230.g004}

![Prenatal *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ mice show reduced chondrocyte proliferation and defects in hypertrophic differentiation.\
(A, B) Sections of E14.5 control and *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ mutant forelimbs stained with Safranin-Weigert. The length of the zone of hypertrophic chondrocytes is reduced in *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ mutant mice. Measurements for B are visualized with white (control) and black (mutant) left-right arrows. HC = hypertrophic chondrocytes; PC = proliferating chondrocytes. (C, D) BrdU labeling of E14.5 control and *Atoh8*^*flox/flox*^*;Prx1-Cre* forelimb sections revealed a reduced proliferation rate in columnar chondrocytes in *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ mice. Regions of round and columnar chondrocytes analyzed in D are framed with white boxes. (E) Alcian blue staining of chondrocytes cultured in high-density for 14 days in control or differentiation medium. Primary chondrocytes were isolated from E12.5 control and *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ mutant embryos. The number of cartilage nodules is decreased in micromass cultures of mutant mice. (F) Sections of E12.5 control and *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ forelimbs stained with Safranin-Weigert do not show obvious differences in size of cartilage anlagen. (B) n = 18 control and 17 *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ mice from 8 litters; (D) n = 12 control and 11 *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ biological replicates from 5 litters; (B, D) Bayesian analysis. Scale bar in A: 500 μm and in C: 100 μm (white lines), in F: 500 μm (black lines).](pone.0218230.g005){#pone.0218230.g005}

To investigate if Atoh8 also affects the differentiation of chondrocytes prenatally, we analyzed the regions of proliferating and hypertrophic chondrocytes after *in situ* hybridization with *Col2*, *Ihh* and *Col10* antisense probes ([Fig 4C](#pone.0218230.g004){ref-type="fig"}) in *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ mice at E16.5. Measuring the size of the Col2 expression domain (*p*~*+*~ = 0.016) and the distance of the Col10 (*p*~*+*~ \< 0.001) and Ihh (*p*~*+*~ = 0.020) expression domains to the joint, we found a reduced region of proliferating chondrocytes at E16.5, while the region of hypertrophy demarcated by the Col10 expression domain was also reduced at this stage but not as clearly (*p*~*+*~ = 0.062) ([Fig 4E](#pone.0218230.g004){ref-type="fig"}).

Morphological analysis of Safranin-Weigert stained sections of E14.5 control and *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ forelimbs revealed a reduced size of the skeletal elements and a reduced region of proliferating chondrocytes already at this early time. In addition, the hypertrophic region is significantly shorter in mutant radii (*p*~*+*~ \< 0.001) ([Fig 5A and 5B](#pone.0218230.g005){ref-type="fig"}). To test if chondrocyte proliferation is also affected prenatally, we labeled proliferating cells of E14.5 mice with BrdU. We found that compared to control littermates the proliferation rate of columnar chondrocyte of *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ mice was reduced by 2.4% (*p*~*+*~ \< 0.001) ([Fig 5C and 5D](#pone.0218230.g005){ref-type="fig"}). As the initiation of hypertrophic differentiation requires a critical size of the skeletal element, the observed reduced hypertrophic region is likely a consequence of the reduced proliferation rate. In accordance, Alcian blue staining of micromass cultures revealed a reduced differentiation capacity of *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ chondrocytes under differentiation conditions ([Fig 5E](#pone.0218230.g005){ref-type="fig"}). Since Col2 expression is generally decreased in Atoh8-deficient micromass cultures ([Fig 1G](#pone.0218230.g001){ref-type="fig"}), the reduced formation of cartilage nodules seems also be a consequence of decreased chondrocyte proliferation.

To investigate if the more severe phenotype in *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ mice is based on defects in mesenchymal condensation, we analyzed cartilage anlagen of E12.5 limb buds, but could not detect differences between mutant and control mice ([Fig 5F](#pone.0218230.g005){ref-type="fig"}).

In summary, ubiquitous deletion of Atoh8 results in a reduced proliferation rate and consequently a delayed initiation of hypertrophic differentiation at early stages. At later stages the proliferation rate remains reduced, while the switch from proliferation to hypertrophy is accelerated leading to reduced regions of proliferating chondrocytes. Since the condensation of mesenchymal cells is not obviously affected, the increased severity of the phenotype compared to that of *Atoh8*^*flox/flox*^*;Col2a1-Cre* mice is likely due to a temporal delay in Atoh8 inactivation by the Col2a1 driven recombination.

Calcineurin does not regulate nuclear localization of Atoh8 in chondrocytes {#sec018}
---------------------------------------------------------------------------

The calcium- and calmodulin-dependent serine/threonine protein phosphatase Calcineurin has been identified as an interaction partner of Atoh8 regulating its nuclear localization \[[@pone.0218230.ref030]\]. The authors showed that in HEK293 cells Calcineurin inhibition by Cyclosporine A (CsA) prevents the translocation of Atoh8 from the cytoplasm to the nucleus \[[@pone.0218230.ref030]\]. Since Calcineurin is known to regulate chondrogenesis \[[@pone.0218230.ref033]\], we asked if Calcineurin also controls the nuclear localization of Atoh8 in chondrocytes. For this purpose, we overexpressed an Atoh8-ECFP fusion protein in the chondrogenic cell line ATDC5 \[[@pone.0218230.ref029]\] and treated the cells with different concentrations of CsA. Fluorescence microscopy revealed that Atoh8-ECFP is primarily located in the nucleus in untreated cells ([Fig 6A](#pone.0218230.g006){ref-type="fig"}). Interestingly, while treatment with CsA clearly reduced nodule formation in micromass cultures as published previously ([Fig 6B](#pone.0218230.g006){ref-type="fig"}) \[[@pone.0218230.ref034]\], we could not detect an increased cytoplasmic localization of Atoh8 due to Calcineurin inhibition in ATDC5 cells ([Fig 6A](#pone.0218230.g006){ref-type="fig"}). In conclusion, our results indicate that in contrast to HEK293 cells the cellular localization of Atoh8 is not regulated by Calcineurin in chondrocytes.

![The nuclear localization of Atoh8 is Calcineurin-independent in chondrocytes.\
(A) Fluorescence images of hAtoh8-CFP overexpressing ATDC5 cells treated with different concentration of CsA for 24 h. CsA treatment does not change the nuclear localization of Atoh8. Scale bar (white lines): 10 μm. (B) Alcian blue staining of chondrocytes cultured in high-density for 14 days in control or differentiation medium. Primary chondrocytes were isolated from E12.5 wild-type embryos and treated with 10 μM CsA or DMSO as a control. The number of cartilage nodules is decreased in micromass cultures treated with CsA.](pone.0218230.g006){#pone.0218230.g006}

Atoh8 regulates onset of hypertrophic differentiation upstream and chondrocyte proliferation independent or downstream of Ihh signaling {#sec019}
---------------------------------------------------------------------------------------------------------------------------------------

Since Atoh8 shows an increased expression in prehypertrophic chondrocytes where the expression of Ihh is initiated ([Fig 1D](#pone.0218230.g001){ref-type="fig"}) and both, the region of proliferating chondrocytes and the proliferation rate, are regulated by Ihh signaling \[[@pone.0218230.ref002], [@pone.0218230.ref003]\], we analyzed a potential interaction of Atoh8 and Ihh signaling. To activate Ihh signaling, we treated limb explant cultures of E16.5 control and *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ mice with the Smoothened agonist Purmorphamine. We used *in situ* hybridization with a *Col2* antisense probe to identify the domain of proliferating chondrocytes, and BrdU incorporation to determine the proliferation rate. As expected, the size of the Col2 expression domain was significantly increased by Purmorphamine treatment in control mice (*p*~*-*~ \< 0.001). Similarly, the region of proliferating chondrocytes was significantly enlarged in Purmorphamine-treated *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ limb explants (*p*~*-*~ \< 0.001) ([Fig 7A and 7B](#pone.0218230.g007){ref-type="fig"}). In contrast, the effect of the Purmorphamine treatment on chondrocyte proliferation was significantly reduced in *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ compared to control limb explants. While the activation of Ihh signaling caused an upregulation of the proliferation rate by 1.1% in round (*p*~*-*~ \< 0.001) and by 3.2% in columnar (*p*~*-*~ \< 0.001) chondrocytes of control embryos, it did not or only slightly increase the proliferation rate of round (*p*~*-*~ = 0.397) and columnar chondrocytes (*p*~*-*~ = 0.010) in *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ limb explants ([Fig 7C and 7D](#pone.0218230.g007){ref-type="fig"}). These results indicate that Atoh8 acts independent or downstream of Ihh signaling in determining the rate of chondrocyte proliferation. In contrast, the size of the domain of proliferating chondrocytes seems to be regulated by Ihh downstream of Atoh8. This was supported by qRT-PCR analyses of E14.5 and E16.5 forelimb skeletal elements revealing a significantly reduced Ihh expression in *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ mutants at both stages (*p*~*+*~ = 0.014 and *p*~*+*~ = 0.008) ([Fig 7E](#pone.0218230.g007){ref-type="fig"}). Consistently, the Ihh signal detected by *in situ* hybridization of E16.5 embryos seems to be weaker in *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ mice compared to control littermates ([Fig 4C](#pone.0218230.g004){ref-type="fig"}). In summary, Atoh8 regulates the onset of hypertrophic differentiation upstream of Ihh, while it has an Ihh independent effect or acts downstream of Ihh on the proliferation rate.

![Atoh8 seems to regulate chondrocyte proliferation in parallel or downstream but hypertrophic differentiation upstream of Ihh signaling.\
(A, B) Sections of limb explants hybridized with a *Col2* antisense probe. Limb explants of E16.5 control and *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ forelimbs were cultured for 96 h with 4 μM Purmorphamine (Pur.) or DMSO as a control. Measurements for B are visualized with white (untreated) and black (treated) left-right arrows. The zone of proliferating chondrocyte is enlarged in control and *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ radii after Purmorphamine treatment. (C, D) BrdU labeling of E16.5 control and *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ limb explants, which were cultured for 48 h with 4 μM Purmorphamine (Pur.) or DMSO as a control. Regions of round and columnar chondrocytes analyzed in D are framed with white boxes. Activation of Ihh signaling by Purmorphamine increases chondrocyte proliferation in control limb explants more than in *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ explants. (E) qRT-PCR of E14.5 and E16.5 control and *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ forelimb skeletal elements revealed reduced Ihh expression in mutant mice at both stages. (B) n = 2 control and *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ mice from 1 litter; (D) n = 9 control and 8 *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ mice from 4 litters; (E) n = 12 control and 10 *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ mice from 6 litters (E14.5), n = 9 control and 10 *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ mice from 5 litters (E16.5); (B, D, E) Bayesian analysis. Scale bar (white lines) in A and C: 500 μm.](pone.0218230.g007){#pone.0218230.g007}

Discussion {#sec020}
==========

Members of the *Atonal* gene family, e.g. *Atoh1* and *Atoh7*, have been associated with the development of sensory neurons and are typically classified as proneuronal genes \[[@pone.0218230.ref035]--[@pone.0218230.ref037]\]. Here we have investigated the role of Atoh8, a less well characterized member of the protein family, which is widely expressed in the developing embryo \[[@pone.0218230.ref008], [@pone.0218230.ref009], [@pone.0218230.ref014], [@pone.0218230.ref038], [@pone.0218230.ref039]\].

The general role of Atoh8 during embryonic development has been controversially discussed, since the phenotypic spectrum of mouse mutants reaches from early embryonic lethality \[[@pone.0218230.ref039]\] to no severe phenotypical alterations in an independently derived loss of function mouse line \[[@pone.0218230.ref040]\]. A mild phenotype has also been described after pancreas-specific inactivation of a conditional Atoh8 allele \[[@pone.0218230.ref041]\]. In this study, we have used an independently generated conditional Atoh8 allele to induce a chondrocyte-specific and a ubiquitous inactivation of Atoh8 in mice. Both mutants show a reduced skeletal size, but are viable and survive until adulthood. Since no other *Atoh* gene is expressed in control or Atoh8-deficient developing skeletal elements, it can be excluded that the bone phenotype of Atoh8-deficient mice is diminished due to a functional redundancy or compensation by other Atoh proteins. This strongly supports a role of Atoh8 in fine tuning developmental processes rather than being required for survival.

Detailed analysis revealed a decreased chondrocyte proliferation rate, which is likely responsible for the decreased bone length. Furthermore, both mutant lines show reduced regions of proliferating and hypertrophic chondrocytes indicating an additional role of Atoh8 in controlling the differentiation process. To exclude that the reduced skeletal size is due to defects in the condensation we analyzed mice at E12.5, but could not detect any differences in skeletal size. Consistent with this, deleting Atoh8 under the Col2-promoter, which is active after the chondrocyte fate is established, also reduces the proliferation rate and accelerates hypertrophic differentiation strongly indicating a direct role of Atoh8 in both processes.

Corresponding to our results, Atoh8 has been identified as a regulator of proliferation and differentiation in other tissues. Nevertheless, its function seems to be quite variable depending on the tissue type. For instance, in endothelial cells and podocytes Atoh8 has been identified as a negative regulator of proliferation \[[@pone.0218230.ref009], [@pone.0218230.ref042]\] while in chondrocytes (this study), in regenerating mouse myoblasts \[[@pone.0218230.ref010]\] and in colorectal cancer Atoh8 \[[@pone.0218230.ref011]\] seems to activate the proliferation rate. Different sets of interacting factors are thus likely to determine the cell type specific function of Atoh8 as a regulator of proliferation.

Although little is known about the proteins that interact with Atoh8, the serine/threonine protein phosphatase Calcineurin has recently been shown to regulate its nuclear localization in HEK293 cells. While in untreated cells Atoh8 was mainly located in the nucleus, inhibition of Calcineurin by CsA led to the retention of Atoh8 in the cytoplasm \[[@pone.0218230.ref030]\]. Interestingly, Calcineurin has also been identified as a regulator of chondrocyte differentiation \[[@pone.0218230.ref033]\]. In chondrocytes Calcineurin controls the nuclear localization of Nfat transcription factors and consequently the expression of chondrocyte-specific regulators including Sox9, Bmp2, Fgf18 \[[@pone.0218230.ref034], [@pone.0218230.ref043], [@pone.0218230.ref044]\] and a large number of extracellular matrix components like Acan, Col2a1, Col9a1, Col11a1 and Col10a1 \[[@pone.0218230.ref045], [@pone.0218230.ref046]\]. To test if Calcineurin regulates the cellular localization of Atoh8 in chondrocytes, we inhibited its function by CsA treatment in the chondrogenic cell line ATDC5, but could not detect any indication of an increased cytoplasmic Atoh8 localization. The dependency of nuclear Atoh8 localization on Calcineurin activity seems thus be specific for other cell types.

To integrate Atoh8 into the regulatory network of chondrocytes, we next investigated a potential interaction with Ihh signaling, which regulates the proliferation rate and the pool of proliferating chondrocytes \[[@pone.0218230.ref002], [@pone.0218230.ref003], [@pone.0218230.ref047]\]. Ihh is expressed in prehypertrophic chondrocytes and its expression domain overlaps with the region of increased Atho8 expression at the border between proliferating and hypertrophic chondrocytes. While chondrocyte proliferation is directly regulated by Ihh secreted from prehypertrophic cells \[[@pone.0218230.ref048], [@pone.0218230.ref049]\], the pool of proliferating chondrocytes is regulated indirectly by the Ihh-dependent expression of parathyroid hormone related peptide (PTHrP) in round chondrocytes. PTHrP in turn acts back on proliferating chondrocytes, where it prevents the onset of hypertrophy \[[@pone.0218230.ref005], [@pone.0218230.ref050]\]. Interestingly, the expression of Ihh detected by *in situ* hybridization and qRT-PCR and, subsequently, the region of proliferating chondrocytes is reduced in Atoh8 mutants indicating that the Ihh/PthrP system acts downstream of Atoh8 on the onset of differentiation. This is supported by limb explant cultures treated with the hedgehog agonist Purmorphamine, which rescued the reduced region of proliferating cells in Atoh8-deficient explants. In contrast, activation of Ihh signaling by Purmorphamine did not fully rescue the proliferation rate in limb explant cultures of Atoh8-deficient mice strongly supporting an Ihh independent role of Atoh8 in regulating chondrocyte proliferation. If Atoh8 really acts in parallel or alternatively downstream of Ihh has to be investigated in future studies.

Similar to Atoh8, Fibroblast growth factor (Fgf) and Bone morphogenetic protein (Bmp) signaling have been shown to regulate chondrocyte proliferation independent of Ihh, whereas they modulate the onset of hypertrophy by affecting Ihh expression. While Bmp signaling induces proliferation and Ihh expression, Fgf signals inhibit both processes \[[@pone.0218230.ref051], [@pone.0218230.ref052]\]. Atoh8 might thus act downstream of either signaling system or act on proliferation and differentiation as an independent regulator downstream of yet not identified mechanisms.

With respect to a potential interaction of Ihh signaling and Atoh8 function it is interesting to note that E-box elements, the typical target sequence of bHLH proteins, have been identified as unusual targets of Gli transcription factors \[[@pone.0218230.ref053]\], the main mediators of Ihh signaling. Accordingly, Atoh8 and Gli might interact at these elements to regulate target gene expression. In preliminary co-immunoprecipitation experiments we could, however, not detect an interaction of Atoh8 and Gli3 (unpublished). Nevertheless, the proteins might interact in larger complexes or competitively bind to these target sequences. Alternatively, Atoh1 has been reported to regulate the transcription Cep131 and thereby influences the maintenance of the primary cilium, an essential organelle for Ihh signal transduction \[[@pone.0218230.ref054]\]. Aoth8 might have a similar function and regulate Ihh/Gli3 via modification of cilia structure.

In conclusion, we identified Atoh8 as a regulator of endochondral ossification, which increases the pool of proliferating chondrocytes by activating the rate of chondrocyte proliferation and inhibiting the onset of hypertrophic differentiation. Our data further demonstrate that Atoh8 acts upstream and in parallel or downstream of Ihh in regulating the onset of hypertrophy and the proliferation rate, respectively. Atoh8 thus represents a new factor controlling the tight balance between proliferation, cell cycle exit and hypertrophy, a critical step to coordinate bone growth.

Supporting information {#sec021}
======================

###### Targeting strategy for Atoh8 deletion in mice.

Schematic representation of wild-type (A), targeted (B) and recombined (C) *Atoh8* gene locus. Exon 1 is flanked by two *loxP* sites \[[@pone.0218230.ref017]\]. Genotyping primers are shown as black arrows, the length of corresponding PCR products in bp are listed in between.

(PDF)

###### 

Click here for additional data file.

###### Comparison of control, heterozygous and homozygous Atoh8 deleted mice.

\(A\) Radius length of P7 control, *Atoh8*^*flox/+*^*;Col2a1-Cre* and *Atoh8*^*flox/flox*^*;Col2a1-Cre* mice. (B, C) Radius length of E14.5 (B) and E16.5 (C) control, *Atoh8*^*flox/+*^*;Prx1-Cre*^*female*^ and *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ mice. (A) n = 10 control, 6 *Atoh8*^*flox/+*^*;Col2a1-Cre* and 8 *Atoh8*^*flox/flox*^*;Col2a1-Cre* mice from 5 litters; (B) n = 18 control, 8 *Atoh8*^*flox/+*^*;Col2a1-Cre* and 17 *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ mice from 8 litters; (C) n = 5 control, 3 *Atoh8*^*flox/+*^*;Col2a1-Cre* and 5 *Atoh8*^*flox/flox*^*;Prx1-Cre*^*female*^ mice from 2 litters; Bayesian analysis.

(PDF)

###### 

Click here for additional data file.

###### Radius length of prenatal *Atoh8^flox,flox^*;*Col2a1-Cre* mice is not reduced.

Radius length of E16.5 control and *Atoh8*^*flox/flox*^*;Col2a1-Cre* mice are comparable. n = 2 control and *Atoh8*^*flox/flox*^*;Col2a1-Cre* mice from 2 litters; Bayesian analysis.

(PDF)

###### 

Click here for additional data file.

###### *Atoh8* is the only *Atoh* gene which is noteworthy expressed in chondrocytes.

Relative Atoh1 (A), Atoh2 (B), Atoh3 (C), Atoh4 (D), Atoh5 (E), Atoh7 (F) and Atoh8 (G) mRNA expression of NMRI embryos (grey) or control (white) and *Atoh8*^*flox/+*^*;Prx1-Cre*^*female*^ (black) forelimb skeletal elements. n = 2 wild-type mice from 2 litters; n = 4 control and 3 *Atoh8*^*flox/+*^*;Prx1-Cre*^*female*^ mice from 2 litters.

(PDF)

###### 

Click here for additional data file.

###### Overview about calculated *p~-~* and *p~+~* values.

The probability of a negative effect (*p*~*-*~) and a positive effect (*p*~*+*~) caused by an Atoh8 deletion or a Purmorphamine treatment were determined by Bayesian analysis. All calculated *p*~*-*~ and *p*~*+*~ values for the different experiments are listed in this table.

(PDF)

###### 

Click here for additional data file.

###### Overview of additional primer pairs used for the expression analysis of the different *Atoh* genes by qRT-PCR.

(PDF)

###### 

Click here for additional data file.
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The culturs prepared from E12.5 limb buds contain various cell populations. The results from this culture system should not be interpreted as the phenotype of chondrocytes.

To identify and establish very modest differences in size of skeleton and histomorphometric parameter of growth-plate, the authors need to have appropriate control and analyze enough number of specimens. In this study, the authors always used Cre negative littermates as control, but the strains of the parent mice are not given. If the compound mice generated in this study came from more than 2 strains, they need to consider impact of genetic drift on skeletal growth difference. Col2Cre could be an another control mouse. The sample size for analysis of skeleton length is 3-4, which may not be enough to conclude the growth retardation in the mutant mice. It is not provided how many biological different samples were used for histological analysis although the sample size ranges 10-12?. It should be provided how they define the anatomical landmark to orient the limbs and to secure the longest or same tissue level for measurement of various histological parameters.

By searching "GenePaint" database, the reviewer found other members of Atoh families are also expressed in developing skeleton. Are there functional redundancy among other family members? Have you checked expression of other Atoh transcription factors? These points are required to reach conclusion on the exclusive role of Atoh 8 in endochondral ossification.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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1 Aug 2019

Response to reviewer \#1:

1\. The paper is descriptive only, revealing a contributory role for Atoh8 in limb endochondral bone formation but no mechanistic insights. In its technical aspects the work has been carried out to a high standard.

In our publication, we initially describe the bone phenotype of mice with a chondrocyte-specific or a ubiquitous Atoh8 deletion and we show that Atoh8 regulates endochondral bone growth by activating chondrocyte proliferation and inhibiting chondrocyte differentiation. Additionally, functional data from in vivo and in vitro experiments indicates that Atoh8 regulates Ihh expression and in this way modulates the onset of differentiation, while it regulates chondrocyte proliferation either downstream or independent of Ihh. Although the data includes a morphological analysis, it clearly reveals first mechanistic insights into the interaction of Ihh and the transcription factor Atoh8.

2\. The insertion of figure legends in the text is unusual. Maybe it is a policy of the journal? It is a distraction, interrupts the flow of description of Results.

The insertion of figure legends in the text corresponds to the guidelines of PLOS ONE.

3\. Figure 1 needs a better description. Its details and interpretation would not necessarily be obvious to readers of the journal. The zones of limb buds need to be specified clearly in the figure. It is stated that Atoh8 is expressed in the proliferating and hypertrophic zones but especially in prehypertrophic, but it is not so clear in 1C that Atoh8 is expressed in the hypertrophic zone (Col X). Another interpretation is that Atoh8 is not expressed in hypertrophic but appears to be so in prehypertrophic.

For a better visualization of the data summarized in Figure 1, we included a whole-mount in situ hybridization using a Col2 probe (1C, revised version) to demarcate the cartilage templates in the limb buds. Moreover, we added a schematic model showing the zones of proliferating, prehypertrophic and hypertrophic chondrocytes as well as the Col2 and Col10 expression domains (1E, revised version). Atoh8 can be detected in all three chondrocyte populations with stronger expression in prehypertrophic chondrocytes. The hybridization signal is clearly visible in the high-resolution images of the manuscript (tiff file Fig. 1C in the first version or Fig. 1D in the revised version).

4\. Fig 1D and E. What do the micromass culture data mean, apart from showing the knockdown of Atoh8?

As the reviewer states correctly, the verification of the Atoh8 knockdown is one important reason for showing the qPCR data obtained from micromass cultures (Figure 1D and E in the first version or Fig. 1F and G in the revised version). In addition, these data show that Atoh8 expression is maintained during the differentiation process in vitro. Although the expression is very low at d14, it increases again at later stages. This is in line with the results of the Atoh8 in situ hybridization revealing Atoh8 expression in proliferating, prehypertrophic and hypertrophic chondrocytes and with the observation that Atoh8 regulates not only the onset, but also the process of hypertrophic differentiation. Furthermore, the decreased Col2 expression in Atoh8-deficient micromass cultures indicates that the reduced nodule formation is at least partly based on the decreased proliferation of Atoh8-deficient chondrocytes as mentioned on p. 15 lines 385-387 (first version).

5\. Fig 4C and P 13 lines 366 -373. This explanation of Fig 4C is difficult to understand, especially lines 369-371. The authors might explain carefully just exactly how these measurements were made.

For a better representation of our data, we added a schematic representation of the analyzed bone showing the zones of proliferating, prehypertrophic and hypertrophic chondrocytes and the Col2, Ihh and Col10 expression domains in Figure 4 (4D, revised version). We also included a detailed description of how we performed the measurements in the materials and methods section.

6\. Fig 4C. It is impossible to discern any detail in 4C, to the extent that there seems little point in including it if better images are not available. This is particularly so in view of the extremely small. Although statistically significant, difference between columnar cells of control and Atoh-deficient (Fig 5D).

We agree that it is difficult to discern details in Fig. 5C in the PDF file generated upon submission. However, in the original high-resolution image submitted (tiff file) the labeled cells are clearly visible. As the reviewer states correctly, the differences between mutant and control mice are only small at this developmental stage (around 2.5 %). Nevertheless, a slight, but continuously reduced proliferation rate will ultimately lead to a reduced skeletal size.

7\. Fig 6 and Discussion, lines 501-510. The negative outcome of this experiment is not conclusive. Atoh8 is located primarily in the nucleus and cannot be detected in cytoplasm with Csa treatment. Excluding the possibility of Csa outside the nucleus would require more throrough investigation, rather than concluding as has been done in Discussion lines 501 et seq.

It has been shown before that the nuclear Atoh8 translocates to the cytoplasm upon CsA treatment in HEK cells (Chen et al., 2016). In contrast, the results presented here demonstrate that under the same experimental conditions (the same CsA and the same Atoh8-Flag expression construct as used in Chen et al., 2016) the nuclear localization of Atoh8 is not altered by CsA treatment in ATDC5 cells indicating a cell type specific regulation of Atoh8 by Calcineurin. In fact, the potential regulation of Atoh8 by CsA and the corresponding connection to NFAT was one of the reasons we decided to investigate Atoh8 function in chondrocytes. As the reviewer states the result was negative concerning the localization dependency of Atoh8 on Calcineurin. Nevertheless, we thought it is important to publish the cell type specific regulation of Atoh8 localization, while the localization and activity of Calcineurin was not the scope of this study.

8\. Fig 7. The quantitative data in Fig 7 are unconvincing, and in 7C the same comment is made as for Fig 4C (above) -- it is impossible to discern any detail in 7C. Furthermore the quantitative data is so weak that it is difficult to accept the conclusions that Atoh 8 acts upstream and in parallel or downstream of Ihh in regulating the onset of hypertrophy and proliferation rate, respectively (Discussion lines 547-550). Indeed the linkage between Ihh and PTHrP is so strong physiologically that any attempt to reach conclusions about Atoh8 - Ihh relationship in isolation is beset with difficulty.

As discussed for figure 5C, the low quality of Fig. 7C is based on the conversion of a high-resolution tiff file visualizing details to a PDF file.

We fully agree that the interaction of Ihh and Pthrp is complex. While Ihh regulates chondrocyte proliferation independent of Pthrp, the onset of hypertrophic differentiation/pool of proliferating chondrocytes is regulated by the upregulation of Pthrp. Importantly, the expression of Pthrp is strongly dependent on Ihh and reduced Ihh signaling or activation by Purmorphamine treatment is followed by the respective alterations in the Pthrp levels (Han et al., 2016).

Our hypothesis that Atoh8 differentially interacts with Ihh in regulating chondrocyte differentiation and hypertrophy is based on several lines of evidence: The data in Fig. 7E show that the Ihh expression is significantly decreased in Atoh8 mutants (around 40 % at E14.5 and around 70 % at E16.5) indicating that Atoh8 activates Ihh expression. The reduced Ihh expression is linked to an accelerated onset of hypertrophic differentiation as shown in Fig. 3D and 4E placing Atoh8 upstream of the Ihh/Pthrp system. This is supported by data from the limb explant cultures (Fig. 7A and B) demonstrating that activation of the Ihh/PthrP system by Purmorphamine increases the pool of proliferating chondrocytes independent of Atoh8 function.

Reduced Ihh levels will also lead to a reduced chondrocyte proliferation rate. However, the data shown in Fig. 7C and D indicate that activation of Ihh signaling does not rescue the proliferation rate downstream of Atoh8 strongly pointing to an Ihh independent or downstream function of Atoh8. A similar relationship has also been observed for FGF signaling which acts upstream of Ihh on the differentiation (inhibits Ihh expression) and independent or downstream on the proliferation rate (Minina et al. 2002).

In order to clarify the interdependency of Ihh and Pthrp, we changed the discussion in lines 516-528 (first version, see lines 548-561 in the revised version).

Response to reviewer \#2:

1\. The cultures prepared from E12.5 limb buds contain various cell populations. The results from this culture system should not be interpreted as the phenotype of chondrocytes.

We agree that micromass cultures can only supplement morphological in vivo data. In this context, we used this culture system to complement the observations made in the Atoh8 mutants (Fig. 5). The reduced Col2 expression and the reduced nodule formation in Atoh8-deficient cultures are in line with the reduced chondrocyte proliferation and the defects in initial chondrocyte differentiation we found in Atoh8 mutant mice (see also point 4 reviewer 1).

2\. To identify and establish very modest differences in size of skeleton and histomorphometric parameter of growth-plate, the authors need to have appropriate control and analyze enough number of specimens. In this study, the authors always used Cre negative littermates as control, but the strains of the parent mice are not given. If the compound mice generated in this study came from more than 2 strains, they need to consider impact of genetic drift on skeletal growth difference. Col2Cre could be another control mouse. The sample size for analysis of skeleton length is 3-4, which may not be enough to conclude the growth retardation in the mutant mice. It is not provided how many biological different samples were used for histological analysis although the sample size ranges 10-12? It should be provided how they define the anatomical landmark to orient the limbs and to secure the longest or same tissue level for measurement of various histological parameters.

As stated in our discussion Atoh8 deletion results in a modest bone phenotype, which due to the biological variability is difficult to analyze using conventional statistical analyses. Therefore, we implemented a Bayesian probability based statistical analysis, which takes differences between litters and experiments into account and allows to generate meaningful data with relatively low sample sizes and animal numbers.

In addition, we added detailed information about the sample numbers (see figure legends), the numbers of sections analyzed and a more detailed description about how the measurements were performed (see lines 118, 131, 146).

Both Cre lines have been used in multiple studies and no effect of the Cre allele has been published to our knowledge. To further exclude effects of the Cre driver line, we compared the bone length of mutant, heterozygous and control mice (Fig. S2). These data show, that the reduced bone length is based on the Atoh8 deletion and not on the Cre recombinase (Fig. S2). Moreover, we analyzed two mouse strains with different Cre recombinases at different stages in our study (Figures 2, 3, 4 and 5) and found comparable differences between mutants and controls making it unlikely that the effect observed is due to two different Cre alleles.

To exclude strain differences all mouse lines were kept on a C57BL/6J background and mutants were compared to littermates.

3\. By searching \"GenePaint\" database, the reviewer found other members of Atoh families are also expressed in developing skeleton. Are there functional redundancies among other family members? Have you checked expression of other Atoh transcription factors? These points are required to reach conclusion on the exclusive role of Atoh 8 in endochondral ossification.

As the reviewer mentioned, in situ hybridization data of sagittal E14.5 sections available at "GenePaint" indicate an expression of other Atoh genes in the developing skeleton. Based on this, we performed qPCR analyses to test the expression of Atoh1, Atoh2, Atoh3, Atoh4, Atoh5 and Atoh7 in forelimb skeletal elements of E14.5 control and Atoh8-deficient embryos. We could however not detect expression of any of these Atoh genes in control or Atoh8-deficient mice indicating that there is no functional redundancy or compensation during endochondral ossification. We added these results as Fig. S4 to the supplementary material.

###### 

Submitted filename: Response_to_Reviewers_Schroeder_et_al.docx
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Click here for additional data file.
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PONE-D-19-14765R1

Dear Dr. Vortkamp,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Andre van Wijnen

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#2: I Don\'t Know

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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Atoh8 acts as a regulator of chondrocyte proliferation and differentiation in endochondral bones

Dear Dr. Vortkamp:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Andre van Wijnen

Academic Editor

PLOS ONE
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